Moderna huge move
$MRNA just had a wild session, jumping nearly 177% after Moderna and Merck reported positive phase 3 results for their personalized mRNA cancer treatment in melanoma.
The stock had fallen a long way from its pandemic-era highs, so this completely changes the conversation around the company.
Still, the treatment is investigational and regulatory approval is still needed.
Biotech can move fast when clinical data changes the story. Definitely one to watch.
#Moderna #MRNA #BingX
$MRNA just had a wild session, jumping nearly 177% after Moderna and Merck reported positive phase 3 results for their personalized mRNA cancer treatment in melanoma.
The stock had fallen a long way from its pandemic-era highs, so this completely changes the conversation around the company.
Still, the treatment is investigational and regulatory approval is still needed.
Biotech can move fast when clinical data changes the story. Definitely one to watch.
#Moderna #MRNA #BingX